The startup develops a biomarker-based hormone treatment that accurately identifies the specific hormone therapy each patient requires to enhance their chances of conception. This targeted approach enables fertility clinics to optimize treatment protocols prior to in vitro fertilization (IVF), significantly improving pregnancy success rates.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In vitro fertilization (IVF) success rates remain low, and a significant percentage of patients experience adverse side effects due to suboptimal hormone treatments. Clinicians lack reliable biomarkers to determine the most effective hormone protocol for individual patients prior to IVF.
Solution
Dx4Life offers a point-of-care test that enables fertility clinics to personalize hormone treatments for women undergoing IVF, increasing the likelihood of successful conception and reducing the risk of side effects. The test analyzes a novel biomarker to determine the optimal hormone regimen for each patient. The easy-to-use test provides results in under 45 minutes, allowing clinicians to prescribe targeted hormone therapy prior to IVF. By identifying the right hormone treatment for each individual, Dx4Life aims to improve IVF outcomes and patient well-being.
Target Audience
The primary target audience is fertility clinics seeking to improve IVF success rates and minimize side effects for their patients.
Features
- Point-of-care test performed using a simple oral swab
- Rapid results available in under 45 minutes
- Biomarker-based analysis to determine optimal hormone treatment
- Easy-to-interpret visual results